

Corporate Profile

Meridian is a fully integrated life science company that develops, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections. Meridian's diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products and technologies to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers and biotech companies in more than 60 countries around the world. The Company's shares are traded through NASDAQ's Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.

Primary IR Contact

Melissa Lueke
Executive Vice President
Chief Financial Officer
Meridian Bioscience, Inc.

Stock Performance

VIVO (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$16.82
Change (%)	▲ 0.20 (1.20%)
Volume	385,720
52 Week Low	\$13.53
Market Cap	\$705,736,755
Rolling EPS	0.52
PE Ratio	32.1974
Shares Outstanding	42,463,102

Data as of 01/18/19 4:00 p.m. ET



Recent Press Releases

1/7/2019

Meridian Bioscience Announces Preliminary First Quarter 2019 Revenue; First Quarter 2019 Financial Results Conference Call to be Held on January 24, 2019

12/6/2018

Meridian Gets FDA Clearance for New Neonatal Saliva CMV Test

11/8/2018

Meridian Bioscience Reports Fourth Quarter and Full-Year Operating Results, Sets Fiscal 2019 Cash Dividend Rate, and Provides Fiscal 2019 Guidance

10/17/2018

Meridian Bioscience to Hold Fourth Quarter and Full Year 2018 Financial Results Conference Call on November 8, 2018

10/9/2018

DiaSorin and Meridian Enter Into a Strategic Collaboration to Sell Helicobacter Pylori Stool Antigen Test in the United States and in the United Kingdom


Upcoming Events

There are currently no events scheduled.

Recent SEC Filings

Filing Date	Form	Description
01/07/19	8-K	Report of unscheduled material events or corporate event
01/07/19	3	Initial filing by director officer or owner of more than ten percent.
12/13/18	DEF 14A	Official notification to shareholders of matters to be brought to a vote ("Proxy")
12/12/18	8-K	Report of unscheduled material events or corporate event

Analyst Estimates / Ratings



Unable to fulfill request.

Management

Jack Kenny

Chief Executive Officer

Lawrence J. Baldini

Executive Vice President, Global Operations

Melissa A. Lueke

Executive Vice President, Chief Financial Officer

Susan D. Rolih

Executive Vice President, Regulatory Affairs and Quality Assurance

Lourdes G. Weltzien

Executive Vice President, Life Science

Board of Directors

Jack Kenny

Chief Executive Officer

James M. Anderson

Retired President and Chief Executive Officer Cincinnati Children's Hospital

Dwight E. Ellingwood

President, D.E.E. Strategy Consulting, LLC

David C. Phillips

Chairman

John C. McIlwraith

Co-founder Allos Ventures

John M. Rice

Founder and Managing Partner of Triathlon Medical Venture Partners

Catherine A. Sazdanoff

President/ CEO, Sazdanoff Consulting LLC and Business Advisor, Strata Oncology, Inc.

Felicia Williams

Executive Vice President, Controller and Enterprise Risk Officer, Macy's, Inc.

Ownership Summary

Shareholders				
	Holders	Value (\$MM)	% O/S	Shares
Institution	260	606.91	95.5	40,564,357
Mutual Fund	339	389.52	54.4	23,110,780
Insider *	17	16.01	2.5	1,068,546

*Insider values reflect direct beneficial ownership.

Top Holders				
	Shares Held	% O/S	Share Change	Filing Date
BlackRock Institutional Trust Company, N.A.	5,852,926	13.8	294,287	09/30/18
The Vanguard Group, Inc.	4,347,959	10.2	94,180	09/30/18
Brown Capital Management, LLC	3,663,919	8.6	0	09/30/18
Renaissance Technologies LLC	2,801,208	6.6	169,932	09/30/18
Dimensional Fund Advisors, L.P.	1,886,692	4.4	58,358	09/30/18
State Street Global Advisors (US)	1,399,303	3.3	150,149	09/30/18
Systematic Financial Management, L.P.	1,140,424	2.7	8,709	09/30/18
Norges Bank Investment Management (NBIM)	1,136,022	2.7	0	12/31/17
M & G Investment Management Ltd.	1,042,600	2.5	0	09/30/18
Geode Capital Management, L.L.C.	830,415	2.0	22,394	09/30/18

Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.

Minimum 20 minutes delayed